Bluebird bio presents positive long-term data on lyfgenia™ (lovotobegligene autotemcel) gene therapy for sickle cell disease at 66th american society of hematology (ash) annual meeting and exposition

Somerville, mass.--(business wire)--bluebird bio, inc. (nasdaq: blue) today announced new and updated data from lyfgenia™ (lovotobegligene autotemcel, or lovo-cel) gene therapy for patients with sickle cell disease who have a history of vaso-occlusive events (voes). the data will be presented at the 66th american society of hematology (ash) annual meeting and exposition in an oral presentation on sunday, december 8 at 9:30 a.m. pacific time and a poster presentation on sunday, december 8 at 6 p.
ASH Ratings Summary
ASH Quant Ranking